ArticleEuropean journal of nuclear medicine and molecular imaging2026
Interpretive consistency of a qualitative
Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Nuclear medicine in predicting hepatocellular carcinoma response.Nuclear medicine communications · 2026Review
- A multimodal pipeline for the identification and diagnostic immunoPET validation of hepatocellular carcinoma targets for radiotheranostic development.Theranostics · 2026Article
- Clinical Significance of Intratumoral Contrast Pooling on Contrast-Enhanced CT After Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma.Current oncology (Toronto, Ont.) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
purposeAccurate treatment response assessment in HCC is crucial but challenged by interpretive variability on CT/MRI. PSMA has emerged as a theranostic biomarker in HCC; however, interpretive reliability is a prerequisite for its validation against oncologic outcomes. Therefore, we evaluated interpretive consistency of a qualitative
methodsPatients with treatment-naïve HCC were prospectively enrolled for
resultsFrom 88 patients with baseline
conclusionA qualitative PSMA PET framework for HCC treatment response assessment yields nearly perfect interpretive consistency, outperforming CT/MRI-based criteria in post-ICI settings. These findings provide the foundation to validate PSMA-based response against oncologic outcomes in future clinical trials, a critical step toward guiding patient management and accelerating therapeutic innovation in HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.